COMPARISON TOOL
Retatrutide vs AOD-9604 vs Tesamorelin vs MOTS-c
Four different routes to metabolic goals: appetite (retatrutide), fat metabolism (AOD-9604), visceral fat (tesamorelin), and mitochondrial signalling (MOTS-c).
RetatrutideAOD-9604TesamorelinMOTS-cMax 4 peptides
| Property | Retatrutide | AOD-9604 | Tesamorelin | MOTS-c |
|---|---|---|---|---|
| Category | GLP-1 | Metabolic | Growth | Metabolic |
| Type | Peptide | Peptide | Peptide | Peptide |
| Mechanism | Triple agonist (GLP-1 / GIP / glucagon) | hGH fragment 176–191; lipolytic signalling without growth effects | Stabilized GHRH analog | Mitochondrial-derived peptide; AMPK activation |
| Status | Phase 3 | Compounded (Rx) | FDA-approved | Compounded (Rx) |
| Dosing range | 1–12 mg weekly | 250–600 mcg daily | 1–2 mg daily | 2.5–10 mg per dose |
| Frequency | Once weekly | Once daily, morning fasted | Once daily | 2–3× weekly |
| Half-life | ~6 days | Short (limited human data) | ~26–38 minutes | Limited human data |
| Route | Subcutaneous | Subcutaneous | Subcutaneous | Subcutaneous |
| Onset | 1–4 weeks for appetite reduction | 4–8 weeks | 8–12 weeks (visceral fat) | 2–4 weeks |
| Studied for |
|
|
|
|
| Key risks |
|
|
|
|
| Storage | Refrigerated (2–8 °C); use within the pharmacy beyond-use date | Refrigerated (2–8 °C); use within the pharmacy beyond-use date | Refrigerated (2–8 °C); use within the pharmacy beyond-use date | Refrigerated (2–8 °C); use within the pharmacy beyond-use date |
| Available at G1 | Vials: 10 mgShop → | Vials: 5 mg, 10 mgPens: TesaTrim, Lean Recovery, Opti-LeanShop → | Vials: 10 mgPens: Fragment Apex, TesaTrimShop → | Vials: 10 mgPens: MitoforgeShop → |
| Tools | Dosage calculator → | Dosage calculator → | Dosage calculator → | Dosage calculator → |
PROPERTY COMPARISON · RADAR
Profile shape
TYPICAL DOSE RANGES
Dose envelope
Retatrutide1 mg – 12 mg
AOD-9604250 mcg – 600 mcg
Tesamorelin1 mg – 2 mg
MOTS-c2.5 mg – 10 mg
Typical per-dose range on a logarithmic scale. Your provider sets your dose.
For educational purposes only. Consult a licensed provider before starting any peptide protocol.